Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

David F. Moreno, Cristina Jiménez, Fernando Escalante Barrigón, Elham Askari, Mario Arnao, Ángela Heredia, Magdalena Alcalá, Arancha Bermúdez, Ana Saus Carreres, Maria Casanova, Luis Palomera, Cristina Motllo, Ricarda Belen Garcia Sanchez, Ramón García-Sanz, Carlos Fernández De Larrea

Blood (2022) 140 (Supplement 1): 259–260.

https://doi.org/10.1182/blood-2022-163008

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139160

Published: 2020

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MDPhD, Cristina Motllo, Paula Rodriguez-Otero, MD PhD, Joaquin Martinez-Lopez, MD PhD, Javier de la Rubia, Jesús Martín, Joan Bladé, MD PhD, María-Dolores García-Malo, Luis Palomera, Aránzazu García-Mateo, Felipe De Arriba, PhD, Ramón García-Sanz, MD, Albert Oriol, MD, Juan-José Lahuerta, Jesus F. San Miguel, MD, Maria-Victoria Mateos, MD

Blood (2017) 130 (Supplement 1): 1873.

https://doi.org/10.1182/blood.V130.Suppl_1.1873.1873

Published: 2017

Journal Articles

Clinical Outcome and Prognostic Factors of Patients with Richter's Syndrome: Retrospective Multicenter Study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC)

Pau Abrisqueta, MD PhD, Julio Delgado, MD, Miguel Alcoceba, PhD, Marcos González, MD, Ana C Oliveira, MD PhD, Javier Loscertales, MD, Jose Angel Hernandez-Rivas, Christelle Ferra, Raul Cordoba, MD PhD, Lucrecia Yañez, MD, Angeles Medina, MD, Cristina Motllo, Anna Varela, Francesc Bosch

Blood (2017) 130 (Supplement 1): 2995.

https://doi.org/10.1182/blood.V130.Suppl_1.2995.2995

Published: 2017

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MD PhD, Cristina Motlló, MD, Paula Rodriguez-Otero, MD PhD, Joaquín Martínez-López, MD PhD, Javier De La Rubia, Mieke Ptaszynski, Brian Tunquist, Ramon Garcia-Sanz, MD PhD, Albert Oriol, Juan José Lahuerta, MD PhD, Jesús San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD

Blood (2016) 128 (22): 4503.

https://doi.org/10.1182/blood.V128.22.4503.4503

Published: 2016

Journal Articles

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

Blood (2016) 128 (22): 1602.

https://doi.org/10.1182/blood.V128.22.1602.1602

Published: 2016

Journal Articles

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Marc Sorigue, MD, Juan-Manuel Sancho, Santiago Mercadal, MD, Ruben Fernández-Álvarez, MD, Helena Pomares, MD, Olga Garcia, Eva González-Barca, MD PhD, Esther González-García, MD, Miriam Moreno, MD, Cristina Motlló, MD, Montserrat García, MD, Jose-Tomas Navarro, MD PhD, Eva domingo-Domenech, MD, Evarist Feliu, MD PhD, Anna Sureda, MD PhD, Josep-Maria Ribera, MD PhD

Blood (2015) 126 (23): 1510.

https://doi.org/10.1182/blood.V126.23.1510.1510

Published: 2015

Journal Articles

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Laura Rosiñol, MD PhD, Albert Oriol, MD, M Jesús Blanchard, Luis Palomera, Maria-Victoria Mateos, Javier De La Rubia, Miguel T Hernandez, MD, Joaquín Díaz-Mediavilla, Jose Mariano Hernandez, Raquel Jiménez, MD, Cristina Motllo, Juan José Lahuerta, MD PhD, Jesus F. San Miguel, Joan Blade

Blood (2014) 124 (21): 4776.

https://doi.org/10.1182/blood.V124.21.4776.4776

Published: 2014

NARROW

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project)

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Clinical Outcome and Prognostic Factors of Patients with Richter's Syndrome: Retrospective Multicenter Study of the Spanish Chronic Lymphocytic Leukemia (CLL) Study Group (GELLC)

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Frequency and Prognostic Significance of the Presence of Additional Cytogenetic Abnormalitions (ACA) to the Philadelphia (Ph) Chromosome in Young Adults with ACUTE Lymphoblastic Leukemia (ALL) Treated with the ALL Ph08 Trial from the Pethema Group

Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only